With a market cap of $10 billion, Revvity, Inc. (RVTY) is a world supplier of well being sciences options, applied sciences, and providers. The corporate delivers a broad portfolio that features devices, reagents, informatics, software program, imaging applied sciences, DNA sequencing providers, and diagnostic platforms for genetic and infectious illness testing.
Firms valued at $10 billion or extra are usually categorized as “large-cap” shares, and Revvity suits this criterion completely. Serving pharmaceutical and biotechnology corporations, analysis establishments, healthcare suppliers, and authorities businesses, Revvity helps developments in diagnostics, drug discovery, genomics, and public well being.
Shares of the Waltham, Massachusetts-based firm have fallen 33.1% from its 52-week excessive of $129.50. Revvity’s shares have declined 8.8% over the previous three months, lagging behind the Well being Care Choose Sector SPDR Fund’s (XLV) 3.7% achieve over the identical timeframe.
Long term, RVTY inventory is down 22.4% on a YTD foundation, underperforming XLV’s marginal drop. Furthermore, shares of the corporate have decreased 29.1% over the previous 52 weeks, in comparison with XLV’s 11.2% dip over the identical timeframe.
Regardless of a couple of fluctuations, the inventory has been buying and selling beneath its 50-day and 200-day transferring averages since February.
Shares of Revvity tumbled 8.3% on Jul. 28 after the corporate lower its full-year adjusted revenue forecast to $4.85 per share – $4.95 per share, citing weaker demand in China. Gross sales of diagnostic merchandise in China declined by double digits in Q2 2025 as new reimbursement insurance policies tied to Prognosis-Associated Teams (DRGs) drove hospitals to shift from Revvity’s higher-value multiplex exams to lower-priced single-plex alternate options.
Consequently, the corporate expects diagnostics gross sales to develop solely within the low single digits versus its earlier mid-single digit forecast.
In distinction, rival IQVIA Holdings Inc. (IQV) has proven a much less pronounced decline than RVTY inventory. IQV inventory has dipped 4.1% on a YTD foundation and 21.7% over the previous 52 weeks.
Regardless of RVTY’s weak efficiency, analysts stay reasonably optimistic about its prospects. The inventory has a consensus score of “Reasonable Purchase” from 18 analysts in protection, and the imply worth goal of $114.62 is a premium of 33.7% to present ranges.
On the date of publication, Sohini Mondal didn’t have (both instantly or not directly) positions in any of the securities talked about on this article. All info and information on this article is solely for informational functions. This text was initially revealed on Barchart.com